Limits...
Safety and efficacy of calcipotriene plus betamethasone dipropionate topical suspension in the treatment of extensive scalp psoriasis in adolescents ages 12 to 17 years.

Eichenfield LF, Ganslandt C, Kurvits M, Schlessinger J - Pediatr Dermatol (2014)

Bottom Line: The primary endpoint was safety, focusing on calcium metabolism and hypothalamic-pituitary-adrenal axis function.One patient showed signs of mild adrenal suppression at week 4; the patient discontinued treatment and had normal test results at follow-up 4 weeks later.Mean TSS improved from 6.9 at baseline to 2.9 at treatment end (59% improvement).

View Article: PubMed Central - PubMed

Affiliation: Rady Children's Hospital and University of California, San Diego, San Diego, California.

Show MeSH

Related in: MedlinePlus

Serum cortisol concentration 30 minutes after adrenocorticotropic hormone challenge at weeks 4 and 8 according to the average weekly amount of study drug used during the first 4 and 8 weeks. The single patient (patient 1016) with a cortisol concentration below the defined cutoff level for a normal response is indicated in the figure.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4491349&req=5

fig02: Serum cortisol concentration 30 minutes after adrenocorticotropic hormone challenge at weeks 4 and 8 according to the average weekly amount of study drug used during the first 4 and 8 weeks. The single patient (patient 1016) with a cortisol concentration below the defined cutoff level for a normal response is indicated in the figure.

Mentions: Sixteen patients (52%) experienced a total of 20 AEs; 14 were mild in severity and none were serious or lesional/perilesional on the scalp. The most common AEs were cough (n = 3; 10%), oropharyngeal pain (n = 3; 10%), nasopharyngitis (n = 2; 7%), and upper respiratory tract infection (n = 2; 7%). The investigator considered only one AE to be possibly related to study treatment—a patient with laboratory signs of adrenal suppression at week 4 (serum cortisol concentration 16.8 μg/dL at 30 minutes after ACTH challenge; Fig. 2). This adverse drug reaction was judged to be mild. The patient discontinued treatment, and a normal ACTH challenge test was reported at the follow-up visit 4 weeks after the end of study treatment. No other patients showed signs of adrenal suppression.


Safety and efficacy of calcipotriene plus betamethasone dipropionate topical suspension in the treatment of extensive scalp psoriasis in adolescents ages 12 to 17 years.

Eichenfield LF, Ganslandt C, Kurvits M, Schlessinger J - Pediatr Dermatol (2014)

Serum cortisol concentration 30 minutes after adrenocorticotropic hormone challenge at weeks 4 and 8 according to the average weekly amount of study drug used during the first 4 and 8 weeks. The single patient (patient 1016) with a cortisol concentration below the defined cutoff level for a normal response is indicated in the figure.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4491349&req=5

fig02: Serum cortisol concentration 30 minutes after adrenocorticotropic hormone challenge at weeks 4 and 8 according to the average weekly amount of study drug used during the first 4 and 8 weeks. The single patient (patient 1016) with a cortisol concentration below the defined cutoff level for a normal response is indicated in the figure.
Mentions: Sixteen patients (52%) experienced a total of 20 AEs; 14 were mild in severity and none were serious or lesional/perilesional on the scalp. The most common AEs were cough (n = 3; 10%), oropharyngeal pain (n = 3; 10%), nasopharyngitis (n = 2; 7%), and upper respiratory tract infection (n = 2; 7%). The investigator considered only one AE to be possibly related to study treatment—a patient with laboratory signs of adrenal suppression at week 4 (serum cortisol concentration 16.8 μg/dL at 30 minutes after ACTH challenge; Fig. 2). This adverse drug reaction was judged to be mild. The patient discontinued treatment, and a normal ACTH challenge test was reported at the follow-up visit 4 weeks after the end of study treatment. No other patients showed signs of adrenal suppression.

Bottom Line: The primary endpoint was safety, focusing on calcium metabolism and hypothalamic-pituitary-adrenal axis function.One patient showed signs of mild adrenal suppression at week 4; the patient discontinued treatment and had normal test results at follow-up 4 weeks later.Mean TSS improved from 6.9 at baseline to 2.9 at treatment end (59% improvement).

View Article: PubMed Central - PubMed

Affiliation: Rady Children's Hospital and University of California, San Diego, San Diego, California.

Show MeSH
Related in: MedlinePlus